Therefore, as the therapeutic inhibition of YAP/TAZ is currently being evaluated in phase 1 clinical trials that target TEAD, identifying cancers that display the greatest reliance on YAP/TAZ activity is essential for credentialing TEAD inhibitors [45]. The gene discussed is YAP1; the disease is cancer.